| Nkechinye Pamela Omesiete, MD | |
|
1 Atwell Rd, Cooperstown, NY 13326-1301 | |
| (607) 547-6300 | |
| Not Available |
| Full Name | Nkechinye Pamela Omesiete |
|---|---|
| Gender | Female |
| Speciality | Surgery |
| Location | 1 Atwell Rd, Cooperstown, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720465495 | NPI | - | NPPES |
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191209002247 |
News Archive
Chemists at the University of Texas at Arlington have published a new study that indicates that highly variable contamination events registered in and around unconventional oil and gas developments are the result of operational inefficiencies and not inherent to the extraction process itself.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
A single payer, fully government funded health care system has often been equated with core Canadian values. It is often argued that a single insurer, the government, is critical to the integrity of the system. Permitting private health insurance, it is claimed, would weaken the public system.
Despite the high prevalence of mental illness, and high rates of suicide among young Australians, more than half (54%) of all people with mental health issues do not seek help.
Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nkechinye Pamela Omesiete, MD 8921 Maxwell Pl, Philadelphia, PA 19152-1517 Ph: (267) 439-6733 | Nkechinye Pamela Omesiete, MD 1 Atwell Rd, Cooperstown, NY 13326-1301 Ph: (607) 547-6300 |
News Archive
Chemists at the University of Texas at Arlington have published a new study that indicates that highly variable contamination events registered in and around unconventional oil and gas developments are the result of operational inefficiencies and not inherent to the extraction process itself.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
A single payer, fully government funded health care system has often been equated with core Canadian values. It is often argued that a single insurer, the government, is critical to the integrity of the system. Permitting private health insurance, it is claimed, would weaken the public system.
Despite the high prevalence of mental illness, and high rates of suicide among young Australians, more than half (54%) of all people with mental health issues do not seek help.
Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.
› Verified 5 days ago
Stephanie Strauss Oceguera, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3373 Fax: 607-547-6553 | |
Dr. James Bordley Iv, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3909 Fax: 607-547-6325 | |
Dr. Rajanpreet S Chahal, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3909 Fax: 607-547-6325 | |
Elizabeth Anne Lax, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-4625 | |
Dr. Allan R Serviss, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3909 Fax: 607-547-6325 | |
Dr. Karen M Mcginnis, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3471 Fax: 607-547-6784 | |
Dr. Thomas John Langan Iv, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3474 Fax: 607-547-6553 |